Late Stage Cancer

June 16, 2025

Nivolumab Exhibits Enhanced DFS Outcomes in Resected Gastric Cancers

The FDA has approved a new combination regimen for certain patients with esophageal cell squamous cell carcinoma.

April 1, 2025

Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

November 19, 2024

ChemoRT Then Immunochemotherapy Then Surgery Promising in Unresectable Esophageal Cancer

November 16, 2024

Adding Immunotherapy to Neoadjuvant Chemoradiation May Improve Outcomes in Esophageal Cancer

November 13, 2024

Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer

September 3, 2024

Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma

September 1, 2024

Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma

July 26, 2024

ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer

May 21, 2024

The Drug Tevimbra Now Approved For Use in Esophageal Cancer– Finally Some Help For Patients In Great Need

April 26, 2024

Aspirin Linked to Lower Metastasis in Esophageal, Colorectal Cancers

April 4, 2024

FLOT vs CROSS in Resectable GEJ Adenocarcinoma: Which Regimen is Best?